Last updated 2 years ago
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
52 patients around the world
Available in Mexico, United States
Kartos Therapeutics, Inc.
4Research sites
52Patients around the world
This study is for people with
Myeloproliferative syndromes
Myelofibrosis
Polycythemia vera
Essential thrombocythemia
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)High-risk, or intermediate-1 and 2 risk, defined by Dynamic International Prognostic System (DIPSS)ECOG of 0 or 1
- Subjects who are positive for p53 mutation (Arm 1)Prior MDM2 inhibitor therapy or p53-directed therapy (Arm 1)Prior treatment with any JAK inhibitorPrior splenectomySplenic irradiation within 24 weeks prior to randomizationPrior allogeneic stem-cell transplantation or plans for allogeneic stem-cell transplantHistory of major organ transplantGrade 2 or higher QTc prolongationMajor hemorrhage or intracranial hemorrhage within 24 weeks prior to randomization
Sites
Sociedad de Metabolismo y Corazón S.C
Recruiting
Centro de Investigación Clínica de Oaxaca - Oaxaca
Recruiting
Centro de Investigación Médica Aguascalientes - CIMA
Recruiting
Unidad de Investigación CIMA SC
Recruiting
SponsorKartos Therapeutics, Inc.
Study typeInterventional
Conditions
MyelofibrosisPolycythemia veraEssential thrombocythemia
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04878003
